Sciwind Biosciences Co., Ltd. ('Sciwind'), a biopharmaceutical company focused on the discovery and development of innovative therapies for metabolic diseases, announced today that China's National ...

Ozempic isn’t the only drug that mimics the natural GLP-1 hormone, so users feel fuller for longer and eat less. There’s also Zepbound, Mounjaro, Trulicity and Victoza — and many more on the horizon ...

Agency updates guidance after increase in reports of condition to its yellow card scheme ...

Tirzepatide noninferior to dulaglutide with respect to composite of death from cardiovascular causes, myocardial infarction, or stroke. HealthDay News — Tirzepatide is noninferior to dulaglutide with ...

Please provide your email address to receive an email when new articles are posted on . Semaglutide is approved by the FDA for slowing the progression of chronic kidney disease. Liraglutide and ...

Electronic fuel injection revolutionized the auto industry in the 1980s. It came to replace the carburetor in the task of sending fuel to the engine's cylinders but it does much more: it controls ...

Even as OpenAI works to harden its Atlas AI browser against cyberattacks, the company admits that prompt injections, a type of attack that manipulates AI agents to follow malicious instructions often ...

The SURPASS-CVOT trial—the large cardiovascular outcomes study that showed tirzepatide (Mounjaro) compared favorably with dulaglutide (Trulicity; both Eli Lilly) in patients with type 2 diabetes and ...

A new observational study compared the risk for severe gastrointestinal adverse events across dulaglutide, semaglutide, and tirzepatide in patients with type 2 diabetes (T2D). The study found that the ...

No significant increase in hazard ratios seen for GI events for semaglutide versus dulaglutide, tirzepatide versus dulaglutide, tirzepatide versus semaglutide. (HealthDay News) — For patients with ...

HOUSTON — The dual GLP-1/GIP receptor agonist tirzepatide showed significantly greater efficacy than the GLP-1 dulaglutide in the treatment of major kidney outcomes in patients with type 2 diabetes ...

A prespecified analysis of the SURPASS CVOT trial examining patients with high-risk CKD suggested tirzepatide reduces the risk of major kidney events, particularly eGFR decline and albuminuria, ...